MPPG 5.a. Test 7.3 (AAPM TG-119 tests): Gamma passing rate | |||||||||||||||
Multitarget | Mock prostate | Mock head and neck | CShape (easier) | CShape (harder) | |||||||||||
3%/3 mm | 2%/2 mm | 3%/3 mm | 2%/2 mm | 3%/3 mm | 2%/2 mm | 3%/3 mm | 2%/2 mm | 3%/3 mm | 2%/2 mm | ||||||
99.4% | 97.3% | 99.7% | 98.9% | 97.0% | 88.2% | 99.7% | 98.7% | 98.3% | 96.3% | ||||||
MPPG 5.a. Test 7.4 (clinical tests): Gamma passing rate | |||||||||||||||
SRS (DCAT†) | SRS (VMAT‡) | SBRT (DCAT) | SBRT (VMAT) | ||||||||||||
2%/1 mm | 1%/1 mm | 2%/1 mm | 1%/1 mm | 2%/1 mm | 1%/1 mm | 2%/1 mm | 1%/1 mm | ||||||||
99.7% | 99.3% | 96.1% | 92.2% | 100% | 96.8% | 98.2% | 94.8% | ||||||||
MPPG 5.a. Test 7.5 (end-to-end testing): Ion chamber measurement result | |||||||||||||||
SRS (VMAT) | SRS (CCAT* with a 17.5 mm cone) | ||||||||||||||
0.20% | 0.53% | ||||||||||||||